newsfilter
← Latest News
GlobeNewswire·

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival